香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. （深圳市海普瑞藥業集團股份有限公司） （於中華人民共和國註冊成立的股份有限公司） （股份代號：9989） 2025年度業績預告公告 深圳市海普瑞藥業集團股份有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則（「上市規則」）第13.09(2)條及香港法例第571章證券及期貨條例第XIVA 部的內幕消息條文之規定發佈本公告，旨在向本公司股東（「股東」）及公眾人士提 供本公司的財務資料。本公告亦同時在深圳證券交易所發佈，因此，本公告亦根 據上市規則第13.10B條而發出。 以下為本公司連同其附屬公司（「本集團」）的2025年全年業績預告。本業績預告所 載之財務數據未經審計，除經調整的非《國際財務報告準則》下歸屬於上市公司股 東的淨利潤或另有註釋外，本業績預告所載之財務數據根據中國企業會計準則編 製。本 ...

2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 （1）以区间数进行业绩预告的 | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | | 盈利：28,400 万元–37,700 | | 万元 | 盈利：64,674 | 万元 | | | | 比上年同期下降：56.09%–41.71% | | | | | | 扣除非经常性损益 后的净利润 | | 盈利：36,200 | 万元–46,000 | 万元 | 盈利：25,354 | 万元 | | | | 比上年同期增长：42.78%–81.43% | | | | | | 基本每股收益 | | 盈利：0.1936 元/股 | 元/股–0.2569 | | 盈利：0.4408 | 元/股 | 二、与会计师事务所沟通情况 证券代码：002399 证券简称：海普瑞 公告编号：2026-001 深圳市海普瑞药业集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性 ...

Core Viewpoint - The company emphasizes steady operations and enhancing core competitiveness as fundamental principles, aiming to solidify intrinsic value and improve market representation of its value for better investor returns [1] Group 1: Company Strategy - The company is committed to optimizing corporate governance and enhancing information disclosure [1] - The company focuses on investor relations management and increasing cash dividends as part of its market value management efforts [1] Group 2: Goals and Commitments - The company aims to continuously improve its intrinsic value and strive for a more reasonable market reflection of its value [1] - The company is dedicated to providing better returns for investors through its strategic initiatives [1]

（文章来源：证券日报） 证券日报网讯 1月19日，海普瑞在互动平台回答投资者提问时表示，公司以患者临床未满足的需求为 始，通过多种研发模式布局了高度创新的临床管线，并正在积极推进各项新药开发进程。新药研发具有 周期长、投入大、风险高的特点，临床过程和结果存在诸多不确定性，如有重大进展，公司将及时履行 信息披露义务。 ...

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares) [2]. - The main business segments include heparin sodium raw materials, low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization is 18.048 billion yuan, with a trading volume of 87.8751 million yuan and a turnover rate of 0.57% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.0093 million shares, an increase of 691,700 shares from the previous period [9]. Technical Analysis - The average trading cost of the stock is 11.62 yuan, with the current price approaching a resistance level of 12.37 yuan, indicating potential for upward movement if the resistance is broken [6].

Group 1 - The company, Haiprui (002399), indicated that specific operating performance for the year 2025 will be detailed in its annual report for that year [1] - The company's stock price is influenced by various factors, and it aims to enhance communication with capital market investors [1] - The company is committed to better reflecting its intrinsic value in the market capitalization performance, striving to provide better returns for investors [1]

来源：新浪证券-红岸工作室 1月13日，海普瑞涨0.73%，成交额7838.59万元，换手率0.50%，总市值182.38亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 区间今日近3日近5日近10日近20日主力净流入264.46万-158.62万-28.93万-587.36万-643.10万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1698.58万，占总成 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 深圳市海普瑞藥業集團股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09989 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 220,094,500 | | 0 | | 220,094,500 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 220,094,500 | | 0 | | 220,094,500 | | 1. 股份分類 | 普通股 | 股份類別 | H ...

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and strong overseas revenue [2][3]. Company Overview - Established in 1998 and listed in 2010, Hepalink's main business includes the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The company's revenue composition is as follows: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [7]. - As of September 30, 2025, Hepalink achieved a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company's overseas revenue accounts for 93.04%, benefiting from the depreciation of the RMB [3]. - The total market capitalization is 17.079 billion yuan, with a trading volume of 31.2621 million yuan and a turnover rate of 0.22% [1]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed in the last three years [8]. Institutional Holdings - As of September 30, 2025, the eighth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 12.0093 million shares, an increase of 691,700 shares compared to the previous period [9]. Market Activity - The stock experienced a slight decline of 0.26% on December 17, with a net inflow of 429,600 yuan from major investors, representing 0.02% of the total [4][5].

Core Viewpoint - On December 16, 2025, the company announced the election of Mr. Zhang Ping as the employee director of the sixth board of directors through a democratic voting process by the employees [1] Group 1 - The board of directors received a notification from the company's labor union regarding the election [1] - Mr. Zhang Ping's position in the board was changed from non-independent director to employee director [1] - The term of Mr. Zhang Ping as employee director will last until the end of the sixth board's term [1]